Objectives: To assess the distribution and spending by cost-effectiveness category among those drugs with the highest public spending levels in Canada.
Design: Repeated cross-sectional study.
Setting: The Canadian provinces of Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland.